| dc.contributor.author | Karakurt Eryılmaz, Melek | |
| dc.contributor.author | Karaağaç, Mustafa | |
| dc.date.accessioned | 2021-11-01T15:01:57Z | |
| dc.date.available | 2021-11-01T15:01:57Z | |
| dc.date.issued | 2019 | |
| dc.identifier.issn | 1078-1552 | |
| dc.identifier.issn | 1477-092X | |
| dc.identifier.uri | https://doi.org/10.1177/1078155218818250 | |
| dc.identifier.uri | https://hdl.handle.net/11491/6781 | |
| dc.description.abstract | Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Sage Publications Ltd | en_US |
| dc.relation.ispartof | Journal Of Oncology Pharmacy Practice | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Abiraterone | en_US |
| dc.subject | metastatic castration-resistant prostate cancer | en_US |
| dc.subject | hemodialysis | en_US |
| dc.title | Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis | en_US |
| dc.type | article | en_US |
| dc.department | [Belirlenecek] | en_US |
| dc.identifier.volume | 25 | en_US |
| dc.identifier.issue | 8 | en_US |
| dc.identifier.startpage | 2031 | en_US |
| dc.identifier.endpage | 2034 | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.department-temp | [Eryilmaz, Melek Karakurt] Hitit Univ Educ & Res Hosp, Dept Med Oncol, TR-19000 Corum, Turkey; [Karaagac, Mustafa] Necmettin Erbakan Univ, Sch Med, Dept Med Oncol, Konya, Turkey | en_US |
| dc.contributor.institutionauthor | Karakurt Eryılmaz, Melek | |
| dc.identifier.doi | 10.1177/1078155218818250 | |
| dc.authorwosid | Karakurt, Melek / AAO-5495-2020 | |
| dc.description.wospublicationid | WOS:000494855400030 | en_US |
| dc.description.scopuspublicationid | 2-s2.0-85074625126 | en_US |
| dc.description.pubmedpublicationid | PubMed: 31694496 | en_US |
